Research programme: selective cytokine inhibitory drugs - Celgene

Drug Profile

Research programme: selective cytokine inhibitory drugs - Celgene

Alternative Names: CC-5048

Latest Information Update: 15 Apr 2008

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammation; Respiratory tract disorders

Most Recent Events

  • 15 Apr 2008 Discontinued - Preclinical for Respiratory tract disorders in USA (PO)
  • 15 Apr 2008 Discontinued - Preclinical for Inflammation in USA (PO)
  • 15 Apr 2008 Discontinued - Preclinical for Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top